At the time of writing, Keros Therapeutics Inc [KROS] stock is trading at $66.45, up 6.18%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KROS shares have gain 11.42% over the last week, with a monthly amount glided 11.36%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $96 on September 23, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $102 as its price target on June 25, 2024. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $60 on this stock.
For the past year, the stock price of Keros Therapeutics Inc fluctuated between $27.31 and $73.00. Currently, Wall Street analysts expect the stock to reach $102.6 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $66.45 at the most recent close of the market. An investor can expect a potential return of 54.4% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Gross Profit Margin for this corporation currently stands at -4.1% with Operating Profit Margin at -696.15%, Pretax Profit Margin comes in at -620.13%, and Net Profit Margin reading is -620.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.45 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 64.48 points at the first support level, and at 62.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 67.70, and for the 2nd resistance point, it is at 68.96.
Ratios To Look Out For
It is important to note that Keros Therapeutics Inc [NASDAQ:KROS] has a current ratio of 20.37. In addition, the Quick Ratio stands at 20.37 and the Cash Ratio stands at 19.1. Considering the valuation of this stock, the price to sales ratio is 9234.59, the price to book ratio is 5.71.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
